Project Grant R21EB036789
Award Date 8/7/25
Completion Date 7/31/27
Dollars Obligated $437K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Delaware, USA
Similar Awards
- This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is supporting research to develop an efficient synthetic RNA switch that can regulate the timing and dosing of gene therapies delivered via adeno-associated viral (AAV) vectors. The $1,158,262 award to the University of Massachusetts Medical School will fund the...
- This Project Grant award of $1,640,169 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports Synvivia, Inc.'s development of a platform to identify cyclic peptides that can increase the yield and quality of adeno-associated virus (AAV) vectors for gene therapy manufacturing. The key products and services to be delivered include: Demonstrating that Synvivia's cyclic peptide discovery library contains compounds that...
- This Project Grant award of $235,500 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports the development of a microscale robotic system to facilitate adeno-associated virus serotype 4 (AAV4)-mediated gene delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) to the small airway epithelium in cystic fibrosis patients. The...
- This Project Grant award of $374,199 from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, supports the development of an in situ capsid protein and DNA imaging platform to characterize therapeutic adeno-associated virus (AAV) titers. AAV is a leading gene delivery vector for treating human diseases, but safety challenges related to high AAV vector genome titers have resulted in adverse events, including patient deaths. This project aims to create analytical methods...
- This Project Grant award of $349,909.00 from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) will support the development of Nanoengineering Corporation's viral vector sizing tool to improve gene therapy analytics and reduce drug development costs. The funding will enable the commercialization of Nanoengineering's proprietary electrospray differential mobility analysis (ES-DMA) method, which can quickly and accurately measure the size of virus capsids at an...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $275,000 will support the development of a plasmonic nanopore sensor device for quality control of adeno-associated viruses (AAVs) used in gene therapy. The proposed device will enable accurate characterization of AAV payload (single-stranded DNA, double-stranded DNA, or empty) at low, pre-scale-up concentrations to optimize formulations. The project aims to demonstrate the...
- The federal Project Grant award of $673,600.00 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop an RNA-based sensor that can detect changes in both mRNA and miRNA within living cells and mouse models. The objective is to create a programmable, synthetic biology tool that can identify diseased cells based on their RNA profiles and trigger...
- This $314,000 Project Grant was awarded on September 1, 2025 by the National Institute of General Medical Sciences (NIGMS), which administers the Biomedical Research and Research Training program (CFDA 93.859). The grant was awarded to Cellfe, Inc. to optimize their CellFE microfluidic transfection platform for accelerated, scalable same-day sequential gene editing of T cells for allogeneic cell therapies. The project aims to enhance the speed, precision, and scalability of CRISPR-based gene...
- This Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to extend the reach and efficacy of adeno-associated virus (AAV)-based gene therapy by utilizing endogenously produced extracellular vesicles (EVs) to transport engineered transgene mRNA or protein products among cells and across tissues. The $860,750 award to Emory University will...